5313492025-07-012025-09-305313492025-09-305313492025-03-315313492025-04-012025-09-305313492025-07-012025-09-30in-capmkt:OtherExpenses1Member5313492025-04-012025-09-30in-capmkt:OtherExpenses1Member5313492025-07-012025-09-30in-capmkt:ReportableSegments1Member5313492025-07-012025-09-30in-capmkt:ReportableSegments2Member5313492025-04-012025-09-30in-capmkt:ReportableSegments1Member5313492025-04-012025-09-30in-capmkt:ReportableSegments2Member5313492025-07-012025-09-30in-capmkt:ReportableSegments1Member5313492025-07-012025-09-30in-capmkt:ReportableSegments2Member5313492025-04-012025-09-30in-capmkt:ReportableSegments1Member5313492025-04-012025-09-30in-capmkt:ReportableSegments2Member5313492025-07-012025-09-30in-capmkt:ReportableSegments1Member5313492025-09-30in-capmkt:ReportableSegments1Member5313492025-07-012025-09-30in-capmkt:ReportableSegments2Member5313492025-09-30in-capmkt:ReportableSegments2Member5313492025-07-012025-09-30in-capmkt:ReportableSegments1Member5313492025-09-30in-capmkt:ReportableSegments1Member5313492025-07-012025-09-30in-capmkt:ReportableSegments2Member5313492025-09-30in-capmkt:ReportableSegments2Member5313492025-07-012025-09-30ItemsThatWillNotBeReclassifiedToProfitAndLoss15313492025-04-012025-09-30ItemsThatWillNotBeReclassifiedToProfitAndLoss1iso4217:INRiso4217:INRxbrli:shares531349PANACEABIONOTLISTEDINE922B01023PANACEA BIOTEC LIMITEDMain BoardEquity2025-04-012026-03-312025-11-142025-11-04INRLakhsQuarterlySecond quarterMulti segment2025-11-1411:30:002025-11-1415:35:00trueCash Flow IndirectNot applicable2025-07-012025-09-30UnauditedConsolidated14113000006400000014753000004658000001910000010450000047710000021400000834000005227000001694000000-21870000027000000-191700000300000-51900000-516000000-1401000000000-140100000-100000-140200000-139200000-900000-139300000-900000613000001-2.27-2.2700-2.27-2.27Notes: <BR> 1. The financial results for the quarter and half year ended September 30, 2025 were reviewed by the Audit Committee and approved by the Board of Directors of the Company at their respective meetings held on November 14, 2025, and have been reviewed by the statutory auditors of the Company. <BR> 2. The financial results have been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standards (“Ind AS”) notified under the Companies (Indian Accounting Standards) Rule, 2015, as amended from time to time, specified under section 133 of the Companies Act, 2013. <BR> 3. The consolidated financial results of the Company have been prepared by consolidating the reviewed financial results of the Compnay and its material subsidiary for the respective periods, with the management approved financial results of other wholly owned subsidiaries (“WOS”) and the Enterprises over which the Company exercises control (the Company, these subsidiaries and the enterprises hereinafter collectively referred to as “the Group”): <BR> (i) Indian WOS: Panacea Biotec Pharma Limited (“PBPL”) (material subsidiary) and Meyten Realtech Private Limited; <BR> (ii) Overseas WOS: Panacea Biotec (International) S.A. (“PBS”), Panacea Biotec Germany GmbH (WOS through PBS) and Panacea Biotec Inc. (WOS through PBPL); and <BR> (iii) Enterprises over which the Company exercises control*: PanEra Biotec Private Limited and Adveta Power Private Limited. <BR> *considered as a subsidiary for the purpose of consolidation as per Ind AS 110 <BR> <BR> 4. For the half year ended September 30, 2025, the Company has incurred loss (before tax and exceptional items) of Rs.2,977 lakh (half year ended September 30, 2024: loss of Rs.1,368 lakh) and the Group has incurred a loss (before tax and exceptional items) of Rs.2,663 lakh (half year ended September 30, 2024: loss of Rs.1,780 lakh). The surplus funds remaining with the Group out of the sales of pharmaceutical formulations brands in India and Nepal in March 2022 have helped in strengthening the working capital position, setting up new facilities for enhancement of capacities for manufacturing of vaccines drug substance, scaling up its nutrition and pharmaceutical formulations business and pursuing other business opportunities. The Company has already received higher long-term business orders for vaccines from key institutional customers. Based on these measures and continuous efforts to improve the business performance, the management has prepared the financial results on a going concern basis. <BR> 2025-04-012025-09-30UnauditedConsolidated30783000001207000003199000000119290000039200000129500000934300000300000001673000009721000003465300000-266300000140200000-126100000300000-25900000-256000000-1005000000000-100500000-300000-100800000-98700000-1800000-99000000-1800000613000001-1.62-1.6200-1.62-1.62Other Expenses522700000Other Expenses9721000005328500000109830000015650000007760000037780000000700000030000066000000670000000109500000721520000019533000003260000076220000063670000017940000029700000434800000207540000001301100000532980000000125450000006130000082028000008264100000-4350000082206000002290000000004600000233600000379800000206800000053400000873600000018340000016695000001852900000115200000196810000011284000003539000004000000345080000000432440000012545000000Vaccines908100000Formulations503200000Vaccines2030600000Formulations1047700000141130000030783000000014113000003078300000Vaccines-165700000Formulations-26000000Vaccines-208200000Formulations82100000-191700000-1261000000000-191700000-126100000Vaccines8709000000Formulations383600000012545000000012545000000Vaccines3049100000Formulations1275300000432440000004324400000300000001834000006000000-52850000034030000076000002552000000-4382000000173600000851000001674000000-97000002600000021400000-3300000-57000000255000000000-145900000001338000007700000000154000000-770000000000000-253100000000000000000000000025500000073600000-1540000000000000070000000003000000000-23000000-184700000100000-184600000821300000636700000Items that will not be reclassified to profit or loss-100000-100000Items that will not be reclassified to profit or loss-400000-4000000-10000000-100000-300000